Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2019
Pharma industry swamped with no-deal Brexit info, says BIA
27 February 2019 - Deluge comes just as prime minister hints at delay. ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 26 Feb 2019
They can’t get their medicines. So they’re moving to Scotland.
26 February 2019 - Families in England are preparing to leave the country in a desperate bid to obtain a cystic ...
Posted by Michael Wonder on 26 Feb 2019
How will Brexit affect health services in the UK? An updated evaluation
25 February 2019 - All forms of Brexit are bad for health, but some are worse than others. ...
Posted by Michael Wonder on 25 Feb 2019
Family fight for cancer treatment in USA because drugs not available in UK
25 February 2019 - A mother of four from Downham Market in west Norfolk says she won't live to 50 ...
Posted by Michael Wonder on 25 Feb 2019
Prescriptions to rise to £9 from April
25 February 2019 - The government has announced another rise in prescription costs for medicines dispensed on the NHS in ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 20 Feb 2019
NICE terminates appraisal of combination regimen for patients with advanced platinum-sensitive ovarian cancer
20 February 2019 - The treatment regimen is bevacizumab with carboplatin and gemcitabine hydrochloride and paclitaxel. ...
Posted by Michael Wonder on 16 Feb 2019
Alunbrig recommended by NICE for non-small-cell lung cancer
15 February 2019 - NICE has recommended the use of Alunbrig (brigatinib) for treating ALK-positive advanced non-small-cell lung cancer after ...
Posted by Michael Wonder on 15 Feb 2019
NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company
15 February 2019 - NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in ...
Posted by Michael Wonder on 15 Feb 2019
EU, America and China will all get new medicines ahead of Britain after Brexit, drug company boss warns
14 February 2019 - David Meek, the CEO of Ipsen, warns Britain leaving the European Union has seen the country fall ...
Posted by Michael Wonder on 14 Feb 2019
Cystic fibrosis breakthrough: hope for British sufferers as life-saving drug talks resume
14 February 2019 - Britain's cystic fibrosis sufferers have received fresh hope of receiving a life-saving drug after officials agreed to ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 14 Feb 2019
NICE provides first scientific advice on patient preference study design
14 February 2019 - The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided ...
Posted by Michael Wonder on 12 Feb 2019
Cystic fibrosis scandal: fury over US firm's 'refusal' to set price for life-saving drugs
11 February 2019 - A US drugs firm is "playing with people's lives" by refusing to do a deal over Orkambi, ...